The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Manufacturing Considerations for the Development of Lipid Nanoparticles Using Microfluidics
Open accessAbstract
In the recent of years, the use of lipid nanoparticles (LNPs) for RNA delivery has gained considerable attention, with a large number in the clinical pipeline as vaccine candidates or to treat a wide range of diseases. Microfluidics offers considerable advantages for their manufacture due to its scalability, reproducibility and fast preparation. Thus, in this study, we have evaluated operating and formulation parameters to be considered when developing LNPs. Among them, the flow rate ratio (FRR) and the total flow rate (TFR) have been shown to significantly influence the physicochemical characteristics of the produced particles. In particular, increasing the TFR or increasing the FRR decreased the particle size. The amino lipid choice (cationic—DOTAP and DDAB; ionisable—MC3), buffer choice (citrate buffer pH 6 or TRIS pH 7.4) and type of nucleic acid payload (PolyA, ssDNA or mRNA) have also been shown to have an impact on the characteristics of these LNPs. LNPs were shown to have a high (>90%) loading in all cases and were below 100 nm with a low polydispersity index (≤0.25). The results within this paper could be used as a guide for the development and scalable manufacture of LNP systems using microfluidics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0591-y · Cited by 1,636
Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo
Jayaraman, M., Ansell, S. M., Mui, B. L., Tam, Y. K., Chen, J., Du, X., Butler, D., Eltepu, L., Matsuda, S., Narayanannair, J. K., et al. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203263 · Cited by 1,267
Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines
Hassett, K. J., Benenato, K. E., Jacquinet, E., Lee, A., Woods, A., Yuzhakov, O., Himansu, S., Deterling, J., Geilich, B. M., Ketova, T., et al. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.01.013 · Cited by 927
Kauffman, K. J., Dorkin, J. R., Yang, J. H., Heartlein, M. W., DeRosa, F., Mir, F. F., Fenton, O. S., & Anderson, D. G. (2015) · Nano Letters · doi:10.1021/acs.nanolett.5b02497 · Cited by 796
Nonviral delivery of self-amplifying RNA vaccines
Geall, A. J., Verma, A., Otten, G. R., Shaw, C. A., Hekele, A., Banerjee, K., Cu, Y., Beard, C. W., Brito, L. A., Krucker, T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209367109 · Cited by 741 · cited 2×
“Microfluidics has previously been shown to be an effective tool for the manufacture of LNPs [15,16,19,20], liposomes [21–23] and polymer-based nanoparticles [24–26].”
MethodResultThe role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery
Cheng, X., & Lee, R. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.01.022 · Cited by 703
Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA
Belliveau, N. M., Huft, J., Lin, P. J., Chen, S., Leung, A. K., Leaver, T. J., Wild, A. W., Lee, J. B., Taylor, R. J., Tam, Y. K., et al. (2012) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2012.28 · Cited by 685 · cited 2×
“It is located on the surface of the LNPs and it dictates the particle size of the LNPs during manufacture [16].”
BackgroundMethodAdvances in the delivery of RNA therapeutics: from concept to clinical reality
Kaczmarek, J. C., Kowalski, P. S., & Anderson, D. G. (2017) · Genome Medicine · doi:10.1186/s13073-017-0450-0 · Cited by 656 · cited 1×
“In addition, their size and negative charge impede crossing the cell membrane [3].”
BackgroundLipid nanoparticles for nucleic acid delivery: Current perspectives
Samaridou, E., Heyes, J., & Lutwyche, P. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.002 · Cited by 583
Passive mixers in microfluidic systems: A review
Lee, C.-Y., Wang, W.-T., Liu, C.-C., & Fu, L.-M. (2016) · Chemical Engineering Journal · doi:10.1016/j.cej.2015.10.122 · Cited by 550
Controlled Vesicle Self-Assembly in Microfluidic Channels with Hydrodynamic Focusing
Jahn, A., Vreeland, W. N., Gaitan, M., & Locascio, L. E. (2004) · Journal of the American Chemical Society · doi:10.1021/ja0318030 · Cited by 537
Mui, B. L., Tam, Y. K., Jayaraman, M., Ansell, S. M., Du, X., Tam, Y. Y. C., Lin, P. J., Chen, S., Narayanannair, J. K., Rajeev, K. G., et al. (2013) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2013.66 · Cited by 505
Semple, S. C., Klimuk, S. K., Harasym, T. O., Dos Santos, N., Ansell, S. M., Wong, K. F., Maurer, N., Stark, H., Cullis, P. R., Hope, M. J., et al. (2001) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(00)00343-6 · Cited by 454
Microfluidic Mixing and the Formation of Nanoscale Lipid Vesicles
Jahn, A., Stavis, S. M., Hong, J. S., Vreeland, W. N., DeVoe, D. L., & Gaitan, M. (2010) · ACS Nano · doi:10.1021/nn901676x · Cited by 432
On the role of helper lipids in lipid nanoparticle formulations of siRNA
Kulkarni, J. A., Witzigmann, D., Leung, J., Tam, Y. Y. C., & Cullis, P. R. (2019) · Nanoscale · doi:10.1039/c9nr09347h · Cited by 402
Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA
Chen, S., Tam, Y. Y. C., Lin, P. J. C., Sung, M. M. H., Tam, Y. K., & Cullis, P. R. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.059 · Cited by 366
Leung, A. K. K., Hafez, I. M., Baoukina, S., Belliveau, N. M., Zhigaltsev, I. V., Afshinmanesh, E., Tieleman, D. P., Hansen, C. L., Hope, M. J., & Cullis, P. R. (2012) · The Journal of Physical Chemistry C · doi:10.1021/jp303267y · Cited by 360
Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems
Leung, A. K. K., Tam, Y. Y. C., Chen, S., Hafez, I. M., & Cullis, P. R. (2015) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.5b02891 · Cited by 359
A Scalable, Extrusion-Free Method for Efficient Liposomal Encapsulation of Plasmid DNA
Jeffs, L. B., Palmer, L. R., Ambegia, E. G., Giesbrecht, C., Ewanick, S., & MacLachlan, I. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-1873-z · Cited by 307
Judge, A., McClintock, K., Phelps, J. R., & MacLachlan, I. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.09.014 · Cited by 280
Design of lipid nanoparticles for in vitro and in vivo delivery of plasmid DNA
Kulkarni, J. A., Myhre, J. L., Chen, S., Tam, Y. Y. C., Danescu, A., Richman, J. M., & Cullis, P. R. (2017) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2016.12.014 · Cited by 225
Holland, J. W., Hui, C., Cullis, P. R., & Madden, T. D. (1996) · Biochemistry · doi:10.1021/bi952000v · Cited by 223
Paving the Road for RNA Therapeutics
Dammes, N., & Peer, D. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.08.004 · Cited by 218
Blakney, A. K., McKay, P. F., Yus, B. I., Aldon, Y., & Shattock, R. J. (2019) · Gene Therapy · doi:10.1038/s41434-019-0095-2 · Cited by 206
Webb, C., Forbes, N., Roces, C. B., Anderluzzi, G., Lou, G., Abraham, S., Ingalls, L., Marshall, K., Leaver, T. J., Watts, J. A., et al. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119266 · Cited by 201
Self-citationLou, G., Anderluzzi, G., Schmidt, S. T., Woods, S., Gallorini, S., Brazzoli, M., Giusti, F., Ferlenghi, I., Johnson, R. N., Roberts, C. W., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.06.027 · Cited by 172
Self-citationForbes, N., Hussain, M. T., Briuglia, M. L., Edwards, D., ter Horst, J. H., Szita, N., & Perrie, Y. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.11.060 · Cited by 148
Self-citationTHE CROSSFLOW INJECTION TECHNIQUE: AN IMPROVEMENT OF THE ETHANOL INJECTION METHOD
Wagner, A., Vorauer‐Uhl, K., Kreismayr, G., & Katinger, H. W. D. (2002) · Journal of Liposome Research · doi:10.1081/lpr-120014761 · Cited by 133
A strategy for synthesis of lipid nanoparticles using microfluidic devices with a mixer structure
Maeki, M., Saito, T., Sato, Y., Yasui, T., Kaji, N., Ishida, A., Tani, H., Baba, Y., Harashima, H., & Tokeshi, M. (2015) · RSC Advances · doi:10.1039/c5ra04690d · Cited by 123
Pharmacokinetics and biodistribution of recently-developed siRNA nanomedicines
Park, J., Park, J., Pei, Y., Xu, J., & Yeo, Y. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.12.004 · Cited by 116
Roces, C. B., Christensen, D., & Perrie, Y. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-019-00699-y · Cited by 90
Self-citationSato, Y., Hatakeyama, H., Hyodo, M., & Harashima, H. (2015) · Molecular Therapy · doi:10.1038/mt.2015.222 · Cited by 88
Rapid scale-up and production of active-loaded PEGylated liposomes
Roces, C. B., Port, E. C., Daskalakis, N. N., Watts, J. A., Aylott, J. W., Halbert, G., & Perrie, Y. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119566 · Cited by 86
Self-citationContinuous-Flow Production of Injectable Liposomes via a Microfluidic Approach
Zizzari, A. T., Bianco, M., Carbone, L., Perrone, E., Amato, F., Maruccio, G., Rendina, F., & Arima, V. (2017) · Materials · doi:10.3390/ma10121411 · Cited by 72
Lou, G., Anderluzzi, G., Woods, S., Roberts, C. W., & Perrie, Y. (2019) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2019.08.013 · Cited by 69
Self-citationInvestigating the Impact of Delivery System Design on the Efficacy of Self-Amplifying RNA Vaccines
Anderluzzi, G., Lou, G., Gallorini, S., Brazzoli, M., Johnson, R., O’Hagan, D. T., Baudner, B. C., & Perrie, Y. (2020) · Vaccines · doi:10.3390/vaccines8020212 · Cited by 58
Self-citationLiposomal Formulations for Nucleic Acid Delivery
MacLachlan, I. (2007) · CRC Press eBooks · doi:10.1201/9780849387951-16 · Cited by 57
Sato, Y., Okabe, N., Note, Y., Hashiba, K., Maeki, M., Tokeshi, M., & Harashima, H. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.11.022 · Cited by 57
Rodrigueza, W. V., Wheeler, J. J., Klimuk, S. K., Kitson, C. N., & Hope, M. J. (1995) · Biochemistry · doi:10.1021/bi00018a025 · Cited by 48
Transfection reagent Lipofectamine triggers type I interferon signaling activation in macrophages
Guo, X., Wang, H., Li, Y., Leng, X., Huang, W., Ma, Y., Xu, T., & Qi, X. (2018) · Immunology and Cell Biology · doi:10.1111/imcb.12194 · Cited by 43
Roces, C. B., Khadke, S., Christensen, D., & Perrie, Y. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00730 · Cited by 41
Self-citationLiposomal Formulations for Nucleic Acid Delivery
MacLachlan, I. (2007) · CRC Press eBooks · doi:10.1201/9780849387951.ch9 · Cited by 31
Roces, C. B., Hussain, M. T., Schmidt, S., Christensen, D., & Perrie, Y. (2019) · Vaccines · doi:10.3390/vaccines8010010 · Cited by 17
Self-citation
Cited by
Mendes, B. B., Conniot, J., Avital, A., Yao, D., Jiang, X., Zhou, X., Sharf-Pauker, N., Xiao, Y., Adir, O., Liang, H., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00104-y · Cited by 719
Mehta, M., Bui, T. A., Yang, X., Aksoy, Y., Goldys, E. M., & Deng, W. (2023) · ACS Materials Au · doi:10.1021/acsmaterialsau.3c00032 · Cited by 688
Lipid Nanoparticles for Drug Delivery
Xu, L., Wang, X., Liu, Y., Yang, G., Falconer, R. J., & Zhao, C.-X. (2022) · Advanced NanoBiomed Research · doi:10.1002/anbr.202100109 · Cited by 545
Kim, J., Eygeris, Y., Gupta, M., & Sahay, G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.014 · Cited by 514
Microfluidic Devices: A Tool for Nanoparticle Synthesis and Performance Evaluation
Gimondi, S., Ferreira, H., Reis, R. L., & Neves, N. M. (2023) · ACS Nano · doi:10.1021/acsnano.3c01117 · Cited by 376
Metadata
- Authors
- Roces, C. B., Lou, G., Jain, N., Abraham, S., Thomas, A., Halbert, G. W., & Perrie, Y.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2020-11-15
- Volume
- 12
- Issue
- 11
- Pages
- 1095
- ISSN
- 1999-4923 (ISSN-L)
- OpenAlex
- W3103321439
- Cited by
- 321
- References
- 43
- FWCI
- 8.92
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.